Drug profile · INN
quizartinib dihydrochloride
VANFLYTA
quizartinib dihydrochloride (VANFLYTA) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — quizartinib dihydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
quizartinib dihydrochloride (VANFLYTA) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Primary target: Receptor-type tyrosine-protein kinase FLT3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is quizartinib dihydrochloride?
quizartinib dihydrochloride (VANFLYTA) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for quizartinib dihydrochloride?
VANFLYTA is a marketed brand name for quizartinib dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of quizartinib dihydrochloride?
quizartinib dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.